[{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Vitality Institute Medical Products","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Vitality Institute Medical Products","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vitality Institute Medical Products \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vitality Institute Medical Products \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Conmed Pharmaceutical","sponsor":"Tri-Service General Hospital | Tungs\u2019 Taichung Metroharbour Hospital | Chang Gung Memorial Hospital | Taichung Veterans General Hospital | Kaohsiung Medical University | Taichung Tzu Chi Hospital | Fu Jen Catholic University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AST-120","moa":"Ammonia","graph1":"Dermatology","graph2":"Phase IV","graph3":"Conmed Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Conmed Pharmaceutical \/ Tri-Service General Hospital | Tungs\u2019 Taichung Metroharbour Hospital | Chang Gung Memorial Hospital | Taichung Veterans General Hospital | Kaohsiung Medical University | Taichung Tzu Chi Hospital | Fu Jen Catholic University","highestDevelopmentStatusID":"11","companyTruncated":"Conmed Pharmaceutical \/ Tri-Service General Hospital | Tungs\u2019 Taichung Metroharbour Hospital | Chang Gung Memorial Hospital | Taichung Veterans General Hospital | Kaohsiung Medical University | Taichung Tzu Chi Hospital | Fu Jen Catholic University"},{"orgOrder":0,"company":"Derm Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Derm Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Undisclosed"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Zhonghao Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Peking University People's Hospital \/ Zhonghao Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Peking University People's Hospital \/ Zhonghao Pharmaceutical"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Zhonghao Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Peking University People's Hospital \/ Zhonghao Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Peking University People's Hospital \/ Zhonghao Pharmaceutical"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Dermatology","graph2":"Phase IV","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"HJ23","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phenol","moa":"Carbonic anhydrase (CA)","graph1":"Dermatology","graph2":"Phase IV","graph3":"HJ23","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HJ23 \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HJ23 \/ Undisclosed"},{"orgOrder":0,"company":"DMR Research","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"DMR Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DMR Research \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"DMR Research \/ Endo Pharm"},{"orgOrder":0,"company":"University of Miami","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Miami \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Endo Pharm"},{"orgOrder":0,"company":"Charitable Union for the Research and Education of Peyronie's Disease","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"Charitable Union for the Research and Education of Peyronie's Disease","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Charitable Union for the Research and Education of Peyronie's Disease \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Charitable Union for the Research and Education of Peyronie's Disease \/ Endo Pharm"},{"orgOrder":0,"company":"Charitable Union for the Research and Education of Peyronie's Disease","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"Charitable Union for the Research and Education of Peyronie's Disease","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Charitable Union for the Research and Education of Peyronie's Disease \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Charitable Union for the Research and Education of Peyronie's Disease \/ Endo Pharm"},{"orgOrder":0,"company":"Luxurgery","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum-Aaes","moa":"Collagen alpha-1(I) chain; Collagen alpha-1(II) chain; Collagen alpha-1(III) chain","graph1":"Dermatology","graph2":"Phase IV","graph3":"Luxurgery","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luxurgery \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Luxurgery \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"DeNova Research | University of California, San Diego | The Wall Center for Plastic Surgery | Mathew Avram, MD | Laser & Skin Surgery Medical Group, Inc. | Investigate MD, LLC | Biesman, Brian, M.D. | Plastic Surgical Associates of Fort Collins, P.C.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Cch-Aaes","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ DeNova Research | University of California, San Diego | The Wall Center for Plastic Surgery | Mathew Avram, MD | Laser & Skin Surgery Medical Group, Inc. | Investigate MD, LLC | Biesman, Brian, M.D. | Plastic Surgical Associates of Fort Collins, P.C.","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ DeNova Research | University of California, San Diego | The Wall Center for Plastic Surgery | Mathew Avram, MD | Laser & Skin Surgery Medical Group, Inc. | Investigate MD, LLC | Biesman, Brian, M.D. | Plastic Surgical Associates of Fort Collins, P.C."},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cch-Aaes","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Biofrontera","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Biofrontera","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Biofrontera"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"Fibroblast growth factor 23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Alabama at Birmingham \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Dermatology Consulting Services, PLLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Dermatology Consulting Services, PLLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dermatology Consulting Services, PLLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dermatology Consulting Services, PLLC \/ Undisclosed"},{"orgOrder":0,"company":"Skin Sciences, PLLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Skin Sciences, PLLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Skin Sciences, PLLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Skin Sciences, PLLC \/ Undisclosed"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bausch Health"},{"orgOrder":0,"company":"Libbs Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Libbs Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Libbs Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Libbs Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Ghent \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Belgium Health Care Knowledge Centre","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Belgium Health Care Knowledge Centre","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Ghent \/ Belgium Health Care Knowledge Centre"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw | Belgium Health Care Knowledge Centre | University Hospital Ghent","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw | Belgium Health Care Knowledge Centre | University Hospital Ghent","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ ZonMw | Belgium Health Care Knowledge Centre | University Hospital Ghent"},{"orgOrder":0,"company":"University of Miami","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Miami \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Vunakizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"UCB Pharma S.A | Psoriasis Treatment Center of Central New Jersey","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ UCB Pharma S.A | Psoriasis Treatment Center of Central New Jersey","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ UCB Pharma S.A | Psoriasis Treatment Center of Central New Jersey"},{"orgOrder":0,"company":"Innovaderm","sponsor":"CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al"},{"orgOrder":0,"company":"Johann E Gudjonsson","sponsor":"Eli Lilly | Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Phase IV","graph3":"Johann E Gudjonsson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johann E Gudjonsson \/ Eli Lilly | Almirall","highestDevelopmentStatusID":"11","companyTruncated":"Johann E Gudjonsson \/ Eli Lilly | Almirall"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Kyowa Kirin","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Kyowa Kirin"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Jaehwan Kim","sponsor":"AbbVie Inc | National Institute of Arthritis and Musculoskeletal and Skin Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"Jaehwan Kim","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jaehwan Kim \/ AbbVie Inc | National Institute of Arthritis and Musculoskeletal and Skin Diseases","highestDevelopmentStatusID":"11","companyTruncated":"Jaehwan Kim \/ AbbVie Inc | National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of California, San Francisco \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of California, San Francisco \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Carlos Wambier","sponsor":"Sun Pharmaceutical Industries Limited | Brown University | Lifespan | Ocean State Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"Carlos Wambier","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Carlos Wambier \/ Sun Pharmaceutical Industries Limited | Brown University | Lifespan | Ocean State Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"Carlos Wambier \/ Sun Pharmaceutical Industries Limited | Brown University | Lifespan | Ocean State Research Institute"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Prothya Biosolutions","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Prothya Biosolutions","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Prothya Biosolutions"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Northwestern University \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Michigan \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Regeneron Pharmaceuticals | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Regeneron Pharmaceuticals | Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Regeneron Pharmaceuticals | Sanofi"},{"orgOrder":0,"company":"OptiSkin Medical","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"OptiSkin Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OptiSkin Medical \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"OptiSkin Medical \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Eric Simpson","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Eric Simpson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eric Simpson \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Eric Simpson \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Kelch-like ECH-associated protein 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CIPHER PHARMS INC","sponsor":"Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"CIPHER PHARMS INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CIPHER PHARMS INC \/ Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix","highestDevelopmentStatusID":"11","companyTruncated":"CIPHER PHARMS INC \/ Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix"},{"orgOrder":0,"company":"Professor Mikkel \u00d8stergaard","sponsor":"Celgene Corporation | The Danish Rheumatism Association | The Danish Psoriasis Association","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Professor Mikkel \u00d8stergaard","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Professor Mikkel \u00d8stergaard \/ Celgene Corporation | The Danish Rheumatism Association | The Danish Psoriasis Association","highestDevelopmentStatusID":"11","companyTruncated":"Professor Mikkel \u00d8stergaard \/ Celgene Corporation | The Danish Rheumatism Association | The Danish Psoriasis Association"},{"orgOrder":0,"company":"Derm Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Derm Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Undisclosed"},{"orgOrder":0,"company":"Boston University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Boston University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston University \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Boston University \/ Pfizer Inc"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Massachusetts General Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hematoporphyrins","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase IV","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Edward Lain","sponsor":"VYNE Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Edward Lain","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edward Lain \/ VYNE Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Edward Lain \/ VYNE Therapeutics"},{"orgOrder":0,"company":"Dermatology Consulting Services, PLLC","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Dermatology Consulting Services, PLLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dermatology Consulting Services, PLLC \/ Ortho Dermatologics","highestDevelopmentStatusID":"11","companyTruncated":"Dermatology Consulting Services, PLLC \/ Ortho Dermatologics"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Ortho Dermatologics","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Ortho Dermatologics"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"PROCTER AND GAMBLE","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Colloidal Oatmeal","moa":"Skin barrier","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"University of Alabama at Birmingham \/ PROCTER AND GAMBLE","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ PROCTER AND GAMBLE"},{"orgOrder":0,"company":"Evolus","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Evolus \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"RNA | DNA | Thymidylate synthase||Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Clinact","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Clinact","highestDevelopmentStatusID":"11","companyTruncated":"Pierre Fabre \/ Clinact"},{"orgOrder":0,"company":"OptiSkin Medical","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"OptiSkin Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OptiSkin Medical \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"OptiSkin Medical \/ Amgen Inc"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Innovaderm","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Innovaderm"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Alabama at Birmingham \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Eli Lilly"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ AbbVie Inc"},{"orgOrder":0,"company":"Medical University of Graz","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase IV","graph3":"Medical University of Graz","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Medical University of Graz \/ Almirall","highestDevelopmentStatusID":"11","companyTruncated":"Medical University of Graz \/ Almirall"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Cetaphil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cetaphil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DNN.22.17.036","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"Taipei Medical University WanFang Hospital","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital | Oneness Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fespixon","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taipei Medical University WanFang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taipei Medical University WanFang Hospital \/ Kaohsiung Medical University Chung-Ho Memorial Hospital | Oneness Biotech","highestDevelopmentStatusID":"11","companyTruncated":"Taipei Medical University WanFang Hospital \/ Kaohsiung Medical University Chung-Ho Memorial Hospital | Oneness Biotech"},{"orgOrder":0,"company":"Mahidol University","sponsor":"HOE Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"THAILAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Tapioca Starch Stimutex As","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Mahidol University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Mahidol University \/ HOE Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Mahidol University \/ HOE Pharmaceuticals"},{"orgOrder":0,"company":"Alliance Pharmaceuticals","sponsor":"South Florida Family Health and Research Centers","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Vamousse Spray \\'N\\' Go","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Alliance Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Alliance Pharmaceuticals \/ South Florida Family Health and Research Centers","highestDevelopmentStatusID":"11","companyTruncated":"Alliance Pharmaceuticals \/ South Florida Family Health and Research Centers"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Eli Lilly"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"University of Alabama at Birmingham \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Leo Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          March 27, 2024

                          Lead Product(s) : Risankizumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          02

                          Details : Botox (Botulinum Toxin Type A) is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Skin Aging.

                          Product Name : Botox

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 23, 2024

                          Lead Product(s) : Botulinum toxin type A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          03

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Dermatology

                          Study Phase : Phase IV

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          August 09, 2023

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          04

                          Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          August 01, 2023

                          Lead Product(s) : Risankizumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          05

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Dermatology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          January 11, 2023

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          06

                          Details : Botox (Botulinum Toxin Type A) is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Skin Aging.

                          Product Name : Botox

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 12, 2022

                          Lead Product(s) : Botulinum toxin type A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          07

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Dermatology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          November 21, 2022

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          08

                          Details : Upadacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 19, 2022

                          Lead Product(s) : Upadacitinib

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          09

                          Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          June 01, 2021

                          Lead Product(s) : Risankizumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          10

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Dermatology

                          Study Phase : Phase IV

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          March 30, 2021

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner